Manufacturing news briefs – stories you might have missed
Imugene raises $18.2 million from investors Clinical stage immuno-oncology company Imugene has closed the Share Purchase Plan component of its capital raising in conjunction with the acquisition of the exclusive licensing rights to the CD19-directed allogeneic cell therapy. The SPP raised a further $18.2 million for the company. Imugene’s Executive Chairman Paul Hopper said: “With…